Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 15/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2179457 | 0.90 | ANO1 (0.59) | ANO1ANO2 | |
| SCHEMBL2180572 | 0.88 | ANO1 (0.58) | ANO1ANO2 | |
| SCHEMBL2182048 | 0.87 | ANO1 (0.74) | ANO1ANO2 | |
| SCHEMBL7953324 | 0.86 | ANO1 (0.55) | ANO1RAB9AANO2MEN1KMT2A | |
| SCHEMBL12414126 | 0.86 | CASP3 (0.59) | ANO1ALDH1A1LMNAHPGDANO2 | |
| SCHEMBL12756790 | 0.84 | ANO1 (0.54) | ANO1ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL1953059 | 0.83 | ANO1 (0.65) | ANO1RAB9AANO2MEN1KMT2A | |
| SCHEMBL2179169 | 0.81 | ANO1 (0.52) | ANO1ANO2 | |
| SCHEMBL2180097 | 0.80 | ANO1 (0.53) | ANO1ANO2 | |
| SCHEMBL12414156 | 0.79 | ANO1 (0.55) | ANO1ANO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231344-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8372991-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110166159-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231344-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885ALDH1A1 4409/4885LMNA 1306/4885 |
| US-20110166159-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885ALDH1A1 4409/4885LMNA 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.